MGNX News and Press, MacroGenics Inc.

ROCKVILLE, MD, May 14, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Eric Risser, President and CEO of MacroGenics, will participate in a fi...

2026-05-13 16:06:54 ET More on MacroGenics MacroGenics: Oncology Opportunities In Play, But Investing Feels Like A Gamble MacroGenics, Inc. (MGNX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript MacroGenics to sell manufacturing operations to...

Manufacturing operations divestiture sharpens focus on core capabilities in novel drug discovery and development Manufacturing divestiture and expanded monetization of ZYNYZ royalty anticipated to provide up to $202.5 million in combined proceeds ADC pipeline remains on track for multiple d...

2026-05-12 13:36:26 ET Denver, Colorado ( 247marketnews.com ) - Among the session’s standout movers were Quantum Computing, which blasted through more than $1 billion in trading volume after reporting massive revenue growth and expanding its quantum-photonics footprint. Meanwhile...

2026-05-12 07:16:38 ET More on S&P 500 Futures Don't Fight The Tape: The Rally Is Narrow For A Reason SPX Target Registered Upside Chasing In Tech Stocks Surges To Covid Extremes Stock futures slide as doubts grow over U.S.-Iran ceasefire ahead of inflati...

2026-05-11 18:02:35 ET More on MacroGenics MacroGenics: Oncology Opportunities In Play, But Investing Feels Like A Gamble MacroGenics, Inc. (MGNX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript MacroGenics expands ZYNYZ royalty deal with Sag...

•MacroGenics to receive $122.5 million upfront payment from Bora upon closing •Transaction includes transfer of manufacturing site, CDMO operations and associated personnel to Bora ROCKVILLE, MD, May 11, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage b...

2026-05-04 08:50:25 ET More on MacroGenics MacroGenics: Oncology Opportunities In Play, But Investing Feels Like A Gamble MacroGenics, Inc. (MGNX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript MacroGenics gains removal of FDA partial hold o...

ROCKVILLE, MD, May 04, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that it entered into an expanded royalty purchase agreement with S...

2026-04-10 12:51:41 ET Investment Overview MacroGenics ( MGNX ) is a Rockville, Maryland-based biotech, and an investment opportunity I am returning to, admittedly with some trepidation. Five years ago, I covered the company in a note for Seeking Alpha , assigning stock a Bu...